# CLOSE CONFIDENTLY

WITH A PERFORMANCE GUARANTEE

### **VASCADE®**

**Arterial & Venous Closure System** 

### VASCADE MVP®

**Venous Vascular Closure System** 

Small Bore (5-7F)
Arterial/Venous Procedures



Performance Guarantee

Mid-Bore (6-12F; <15F OD) Venous Procedures




### Sharing Risk by Sharing Costs<sup>™</sup>

The VASCADE® and VASCADE MVP® Vascular Closure Systems combine a proprietary collapsible disc technology and an extravascular bioabsorbable collagen patch to enable rapid hemostasis while minimizing complications.

We stand behind the performance of our vascular closure systems and are proud to offer an award winning outcomes based risk-sharing program. In the event of a qualified complication, we will offset some of the associated costs.





# Clinically Proven to Reduce Access Site Complications<sup>1</sup>



- · Peripheral Artery Intervention
- · Coronary Artery Intervention
- · Neurovascular Intervention
- · Vascular Embolization

### **VASCADE MVP®**

**Venous Vascular Closure System** 



## Clinically Proven to Reduce Time to Ambulation<sup>2</sup>



- · Cardiac Ablation
- · Left Arterial Appendage Closure
- · Venous Stenting & Thrombectomy
- · Congential Heart Defect Repair

#### Hover your camera over the QR code to view a product animation

#### **Ordering Information**

Product	Catalog Number	Description	Quantity
VASCADE® 5F	700-500DX-05U	5F Arterial & Venous	1 Box (5 Devices/Box)
VASCADE® 6/7F	700-580I-05U	6/7F Arterial & Venous	1 Box (5 Devices/Box)
VASCADE MVP®	800-612C-10U	6/12F (15F max OD) Venous	1 Box (10 Devices/Box)

The procedures lists are for informational use only as an example of procedures that may fall within the indicated arteriotomy and/or venotomy sizes. Please consult product labels and instructions for use for indications, contraindications, warnings, precautions and adverse events. See VASCADE IFU 2611 and VASCADE MVP IFU 3972.

© 2021, 2022 Haemonetics Corporation. Haemonetics, VASCADE, VASCADE MVP, and Sharing Risk by Sharing Costs are trademarks or registered trademarks of Haemonetics Corporation in the U.S., other countries or both. Haemonetics Corporation I customerserviceNA@haemonetics.com | 800.537.2802 | For a list of worldwide office locations, and contact information, visit www.haemonetics.com/Officelocations | LIT 5398 Rev C - 02.2022 USA



<sup>&</sup>lt;sup>1</sup> Hermiller JB, et al. A prospective, randomized, pivotal trial of a novel extravascular collagen-based closure device compared to manual compression in diagnostic and interventional patients. J Invasive Cardiol. 2015 Mar;27(3):129-36. PMID: 25740963.

Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. JACC Clin Electrophysiol October 2019. DOI: 10.1016/j.jacep.2019.08.013